Core Viewpoint - CVS Health reported earnings that exceeded analysts' expectations and maintained its profit guidance for 2026, which may alleviate concerns among investors regarding ongoing instability in the health-insurance sector [1] Summary by Relevant Categories Earnings Performance - CVS Health's earnings surpassed analysts' forecasts, indicating strong financial performance [1] Profit Guidance - The company has kept its profit guidance for 2026 unchanged, suggesting confidence in its future financial outlook [1] Market Reaction - The positive earnings report may help to calm investors who are anxious due to the persistent turmoil in the health-insurance industry [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission file number: 001-01011 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 05-0494040 (State or ...

Core Insights - CVS Health reported a decline in fourth-quarter profit but exceeded Wall Street estimates, driven by strength in its pharmacy benefit unit and robust prescription volume at its retail pharmacies [1] Financial Performance - The company experienced a decrease in profit for the fourth quarter, yet managed to outperform analysts' expectations [1] - The performance was bolstered by the pharmacy benefit unit, indicating a strong demand for prescription services [1] Business Segments - The pharmacy benefit unit showed significant strength, contributing positively to the overall performance of CVS Health [1] - Retail pharmacies also reported strong prescription volume, which played a crucial role in the company's ability to beat estimates [1]

Fourth Quarter Highlights Full-Year Highlights Operational Highlights 2026 Full-Year Guidance Exhibit 99.1 CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS - David Joyner, CVS Health President and CEO WOONSOCKET, RHODE ISLAND, February 10, 2026 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2025. Financial Results Summary | | | Three | Months | | Ended | | | --- | --- | --- | --- | --- | --- | --- | | | | | Dece ...

Fourth Quarter Highlights Full-Year Highlights Operational Highlights ® 2026 Full-Year Guidance CEO Commentary "Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses. From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America." - David Joyne ...

CVS Health on Tuesday reported fourth-quarter earnings and revenue that beat estimates and reaffirmed the 2026 profit guidance that impressed investors, signaling steady progress in the health-care giant's turnaround plan. "'24 was a tough year for the company. So '25 righted the ship," CVS CFO Brian Newman said in an interview. CVS, which operates one of the largest pharmacy chains in the U.S., sees full-year profit coming in between $7 to $7.20 per share. That's in line with the $7.17 per share that analy ...

Group 1: U.S. Health Insurance Industry - A U.S. House Judiciary Committee investigation into alleged fraud within the Affordable Care Act (ACA) premium subsidy program has intensified, with subpoenas issued to eight prominent health insurers including Elevance Health (ELV), CVS Health (CVS), Centene (CNC), Guidewell, and Oscar Health (OSCR) [2] - The investigation focuses on potential fraud related to premium subsidies in the individual market, particularly as enhanced premium tax credits for ACA coverage expired on January 1 [2] - Reports suggest that without subsidy extensions, premiums for approximately 22 million ACA enrollees could more than double [2] Group 2: European Defense Industry - European nations are advancing discussions to bolster their defense capabilities and reduce reliance on the United States, with proposals for a phased transfer of military responsibilities from the U.S. to Europe over the next five to ten years [3] - This initiative is driven by concerns over potential shifts in U.S. foreign policy and aims to present a plan to the U.S. before the annual NATO leaders' summit in The Hague in June [3] - The discussions involve commitments to increase European defense spending and military capabilities, potentially including the establishment of a joint armed force of at least 100,000 troops [3] Group 3: Eurozone Liquidity Conditions - The European Central Bank (ECB) reported that 37 million euros were borrowed through its overnight loan facility, while a significantly larger amount of 2394.41 billion euros was deposited using the overnight deposit facility [5] - These figures provide insight into liquidity conditions within the Eurosystem, with the marginal lending facility rate at 2.40% and the deposit facility rate at 2.00%, both remaining unchanged [5]

Group 1 - The article provides a market analysis focusing on the S&P 500, State Street® Consumer Staples Select Sector SPDR® ETF, and iShares Expanded Tech-Software Sector ETF [1] - It highlights the performance trends and investment opportunities within these sectors [1] - The analysis is available on Investing.com, indicating a resource for investors seeking detailed insights [1]

Core Viewpoint - CVS Health is a significant player in the healthcare sector, with a diverse range of services and is set to release its quarterly earnings on February 10, 2026, with estimated EPS of $0.99 and revenue of approximately $103.57 billion [1][6] Financial Performance - CVS has consistently exceeded earnings estimates over the past four quarters, indicating strong financial performance [2] - For Q4 2025, analysts expect non-GAAP earnings of $0.99 per share, a decline from $1.19 per share in Q4 2024, potentially influenced by Medicare news [3] Market Valuation - CVS's P/E ratio of 212 suggests that investors are willing to pay a high price for its earnings, reflecting high expectations [3] - The price-to-sales ratio of 0.25 indicates that the market values CVS at 25 cents for every dollar of sales, while the enterprise value to sales ratio of 0.44 reflects its valuation in relation to sales [4] - The enterprise value to operating cash flow ratio of 18.89 highlights how the market values CVS's cash-generating ability [4] Capital Structure - CVS's debt-to-equity ratio of 1.12 shows a moderate use of debt in its capital structure [5] - The current ratio of 0.83 suggests potential liquidity concerns, as CVS has less than one dollar in current assets for every dollar of current liabilities [5] - The earnings yield of 0.47% provides a comprehensive view of CVS's financial health and market valuation [5]

Group 1 - The Federal Reserve's dual mandate will be addressed this week with the release of the January jobs report and the consumer price index [1] - Earnings reports from Cisco Systems, Applied Materials, and Arista are anticipated, which may provide insights into their financial performance and market conditions [1]